Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Two-Way Crossover, Single-Centre Methodologhy Study in Healthy Subjects to Evaluate the Effect of Oral Dosing With AZD8309 on Cells and Inflammatory Biomarkers in Nasal Lavage and Blood After Nasal Challenge With Lipopolysaccharide (LPS).

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jan 2012

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AZD 8309 (Primary)
  • Indications Chronic obstructive pulmonary disease; Rheumatoid arthritis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors AstraZeneca
  • Most Recent Events

    • 21 Feb 2011 New source identified and integrated (ISRCTN: Current Controlled Trials).
    • 21 Feb 2011 Actual end date changed from Oct 2009 to Dec 2010 as reported by ClinicalTrials.gov.
    • 29 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top